Journal of Hematology & Oncology

official impact factor 2.93
Search for
Advanced search
Journal of Hematology & Oncology
Tools
Share this article
Open Access Email this article to a friend

The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner

Shiloh M Martin, Eric Churchill, Hayes McKnight, Christopher M Mahaffey, Yunpeng Ma, Robert T O'Donnell and Joseph M Tuscano*

Journal of Hematology & Oncology 2011, 4:49 doi:10.1186/1756-8722-4-49

Fields marked * are required


Multiple email addresses should be separated with commas or semicolons.